QUIA PHARMA AB (publ) receives observation status

On June 5, 2025, QUIA PHARMA AB (publ) (the "Company") disclosed its annual financial report for 2024 with information on the Company's financial situation.

The rules of Nasdaq First North Growth Market state that an issuer can be given observation status if there is material adverse uncertainty in respect of the issuer's financial position.

With reference to the above, Nasdaq Stockholm AB decides that the shares in QUIA PHARMA AB (publ) (QUIA, ISIN code SE0020678159, orderbook ID 200627) shall be given observation status.

For further information about this exchange notice please contact Enforcement & Investigations, telephone [phone].